Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Microbix BiosystemsMBXBF 49 EV-to-OCF is -8.27 as of Aug. 11, 2026. GuruFocus rates MBXBF with a GF Score™ of 49/100 and a GF Value™ of $0.16 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 1,406 Biotechnology companies, Microbix Biosystems ranks better than 66.43% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Microbix Biosystems's Enterprise Value is $28.60 Mil.
Microbix Biosystems's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $-3.46 Mil. Therefore, Microbix Biosystems's EV-to-OCF for today is -8.27.
The historical rank and industry rank for Microbix Biosystems's EV-to-OCF or its related term are showing as below:
MBXBF'
s EV-to-OCF Range Over the Past 10 Years
Min: -1771.26 Med: 22.91 Max: 6235.18
Current: -8.4
During the past 13 years, the highest EV-to-OCF of Microbix Biosystems was 6235.18. The lowest was -1771.26. And the median was 22.91.
MBXBF's EV-to-OCF is ranked better than 66.43% of 1406
companies
in the Biotechnology industry
Industry Median: -3.515
vs MBXBF: -8.40
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Microbix Biosystems's PE Ratio (TTM) for today is calculated as:
Microbix Biosystems's share price for today is $0.22.
Microbix Biosystems's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.030.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Microbix Biosystems EV-to-OCF Related Terms
Microbix Biosystems EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Microbix Biosystems's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Microbix Biosystems's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Microbix Biosystems EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Microbix Biosystems's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Microbix Biosystems's EV-to-OCF falls into.
Microbix Biosystems's current Enterprise Value is $28.60 Mil.
Microbix Biosystems's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.46 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Microbix Biosystems (MBXBF) has a EV-to-OCF of -8.27 as of Aug. 11, 2026. According to the industry distribution chart, Microbix Biosystems ranks #472 out of 1406 companies in the Biotechnology industry, placing it in the top 33.6%.
Is Microbix Biosystems' EV-to-OCF too high?
Microbix Biosystems' current EV-to-OCF is -8.27. Based on the distribution chart, Microbix Biosystems ranks #472 out of 1406 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Microbix Biosystems has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Microbix Biosystems' EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Microbix Biosystems ranks #472 out of 1406 companies for EV-to-OCF. This puts Microbix Biosystems in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Microbix Biosystems's current EV-to-OCF is -8.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Microbix Biosystems stock overvalued right now?
Based on GuruFocus' analysis, Microbix Biosystems (MBXBF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.16, compared to a current price of $0.22 — trading 37.5% above its estimated fair value. The current EV-to-OCF is -8.27. Microbix Biosystems' overall GF Score™ is 49/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Microbix Biosystems (MBXBF), the current EV-to-OCF is -8.27 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Microbix Biosystems (MBXBF) Overvalued in 2026?
Based on GuruFocus' analysis, Microbix Biosystems stock appears to be overvalued.
The current stock price of $0.22 is trading 37.5% above its estimated GF Value™ of $0.16.
GuruFocus considers Microbix Biosystems to be Significantly Overvalued.
Key valuation signals for MBXBF:
EV-to-OCF: -8.27
GF Value™: $0.16 vs. price of $0.22 (37.5% above fair value)
No single metric tells the full story. See the MBXBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Microbix Biosystems Inc develops biological products and technologies. There are two operating segments: The development, manufacturing, and sale of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows, and viral transport medium to enable collection of patient test samples; and the development and commercialization of novel and proprietary products or technologies such as Kinlytic. Geographically, it derives a majority of revenue from North America and also operates in Europe and other foreign countries.
49GF Score
Get the complete analysis for MBXBF
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MBXBF has been successfully added to your 
